FDA Approves Mirvetuximab Soravtansine-Gynx for Treatment of Platinum-Resistant Ovarian Cancer
In exciting treatment news, the Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (trade name Elahere, made by Immunogen, Inc.), for adults with folate receptor alpha (FRa) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have undergone one to three earlier systemic treatment regimens. The FDA also approved … Continued